Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ed at the end of 2006.

Our process development expenses for the first quarter of 2008 were $35,766 compared to $89,776 for the first quarter of 2007. In the first quarter of 2008, our process development focus continues to be on the scale up to 100-litre production runs. In the first quarter of 2007, our process development focus was on our earlier 40-litre scale up studies.

We still expect that our M&P expenses for 2008 will increase compared to 2007. We have initiated our 40-litre production runs which will continue throughout 2008. As well, we still expect to finalize our 100-litre scale up studies and continue the examination of a lyophilization process for REOLYSIN(R) in 2008. Once our 100-litre process development studies are complete, we expect to transfer our 100-litre manufacturing process to our cGMP manufacturers.

Clinical Trial Program

2008 2007

$ $

-------------------------------------------------------------------------

Direct clinical trial expenses 994,646 683,107

Other clinical trial expenses 48,145 38,510

-------------------------------------------------------------------------

Clinical trial expenses 1,042,791 721,617

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the first quarter of 2008, our direct clinical trial expenses increased to $994,646 compared to $683,107 for the first quarter of 2007. In the first quarter of 2008, we incurred direct patient costs in our six enrolling clinical trials compared to only three actively enrolling clinical trials in the first quarter of 2007.

We still expect our clinical trial expenses to increase i
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 19, 2014 ... biomaterial market will grow at a 12 percent compound ... a result of the aging population and the increasing ... Latin America will also spur demand ... results of dental implant and periodontal treatments. ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Epeius Biotechnologies ( www.epeiusbiotech.com ) announced today that the U.S. ... anti-cancer agent, Rexin-G , the first, and so far ... out and destroy metastatic cancer. According to Dr. Maria Gordon, ... of clinical development, is that the Rexin-G product, with its ...
... ("ShengdaTech" or the "Company") (NASDAQ: SDTH ), ... China, today announced that Mr. Xiangzhi Chen, the Company,s ... CFO and Mr. A. Carl Mudd, lead independent director, ... Conference to be held from March 6-8, 2011 in ...
... 2011 CSL Behring announces a ... released in conjunction with Rare Disease Day 2011 , ... their impact on people,s lives. The Dialogue spanned ... important information and ideas for patients, caregivers and healthcare providers. ...
Cached Biology Technology:Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 2ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... and, new research shows, an infrared laser can make a ... and Vanderbilt University found that pulsed light can pace contractions ... the tissue. The work, "Optical pacing of the embryonic heart," ... Nature Photonics on Aug. 15, 2010. According to ...
... 27 BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time ... Live via phone by dialing 800-860-2442 and asking for the BIO-key call ...
... 13, 2010The easy accessibility of the eye and the ... offer hope for using gene therapy to provide long-term ... Human Gene Therapy, a peer-reviewed journal published by Mary ... replacement of a human gene to preserve photoreceptor function ...
Cached Biology News:A heart beats to a different drummer 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Promising results of gene therapy to treat diseases of the eye 2
...
A camera based compact unit for high speed scanning of 2D barcoded tubes in a cluster rack. This reader has been designed to read both 96 and 48 tube rack configurations and be compatible with common...
...
... enzyme that catalyzes the conversion,of starch ... maltotriose and,dextrins. The level of a-amylase ... are of clinical importance,1-3 while plant ... industry.4, The EnzChek Amylase Assay Kit ...
Biology Products: